Please login to the form below

Not currently logged in
Email:
Password:

Karus names two division heads

Simon Roitt and Peter Finan strengthen research team

karus-Simon-RoittUK-based biopharma Karus Therapeutics has appointed new heads for two of its research divisions.

Dr Simon Roitt joins as head of clinical development and Dr Peter Finan joins as head of biology.

Dr Roitt (pictured right) is formerly director of clinical operations at Roche in the UK, a position he held for nine years. Prior to this he was director of clinical research at GE Healthcare in the UK.

His new colleague Dr Finan joins Karus from Novartis where he spent 16 years. Most recently he was VP, global head – respiratory disease.

In his new role Dr Finan will work on Karus' most advanced programme, a treatment for inflammatory disorders.

Dr Simon Kerry, chief executive of Karus said: “As we develop the business, the recruitment of highly experienced senior talent to our team will be a critical success factor. Simon and Peter both bring valuable clinical and scientific expertise to the Company, to help drive our programmes towards the clinic.”

29th October 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics